Sphera Funds Management LTD. maintained its position in MacroGenics, Inc. (NASDAQ:MGNX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,200 shares of the biopharmaceutical company’s stock at the end of the first quarter. Sphera Funds Management LTD. owned approximately 0.23% of MacroGenics worth $1,510,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in MGNX. BlackRock Advisors LLC increased its stake in MacroGenics by 26.3% in the third quarter. BlackRock Advisors LLC now owns 24,845 shares of the biopharmaceutical company’s stock valued at $743,000 after buying an additional 5,180 shares in the last quarter. BlackRock Fund Advisors increased its stake in MacroGenics by 5.5% in the third quarter. BlackRock Fund Advisors now owns 1,344,292 shares of the biopharmaceutical company’s stock valued at $40,208,000 after buying an additional 69,938 shares in the last quarter. SG Americas Securities LLC bought a new stake in MacroGenics during the third quarter valued at $223,000. Spark Investment Management LLC increased its stake in MacroGenics by 47.0% in the third quarter. Spark Investment Management LLC now owns 390,600 shares of the biopharmaceutical company’s stock valued at $11,682,000 after buying an additional 124,800 shares in the last quarter. Finally, Baker BROS. Advisors LP acquired a new stake in MacroGenics during the third quarter valued at approximately $10,878,000. 83.10% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Shares of MacroGenics, Inc. (NASDAQ:MGNX) traded up 2.70% on Friday, reaching $18.24. 626,197 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $19.23 and its 200-day moving average price is $19.87. The stock’s market capitalization is $638.62 million. MacroGenics, Inc. has a 52 week low of $16.63 and a 52 week high of $33.30.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.99) by $0.09. MacroGenics had a negative net margin of 72.30% and a negative return on equity of 23.24%. The company had revenue of $2.06 million during the quarter, compared to analyst estimates of $5.88 million. Equities analysts predict that MacroGenics, Inc. will post ($3.80) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Sphera Funds Management LTD. Holds Position in MacroGenics, Inc. (MGNX)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/06/16/sphera-funds-management-ltd-has-1510000-position-in-macrogenics-inc-mgnx-updated-updated.html.

Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday, May 3rd. Roth Capital set a $40.00 price objective on shares of MacroGenics and gave the stock a “buy” rating in a research report on Wednesday, March 1st. Stifel Nicolaus restated a “buy” rating and set a $42.00 price objective (down from $51.00) on shares of MacroGenics in a research report on Wednesday, March 1st. BTIG Research reiterated a “buy” rating and issued a $28.00 target price (down from $35.00) on shares of MacroGenics in a research report on Monday, March 6th. Finally, Instinet began coverage on shares of MacroGenics in a research report on Wednesday, March 1st. They issued a “buy” rating and a $41.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $33.80.

In related news, SVP Jon Marc Wigginton sold 5,000 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the sale, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at approximately $700,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.30% of the stock is currently owned by corporate insiders.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.